Disease activity and quality of life in patients with systemic lupus erythematosus: a validation study using the SLE-DAS.

IF 3.4 4区 医学 Q2 RHEUMATOLOGY Clinical and experimental rheumatology Pub Date : 2025-07-01 Epub Date: 2025-03-13 DOI:10.55563/clinexprheumatol/1n8j8d
Fung Lam, Kar Li Chan, Chi Hung To, Chi Chiu Mok
{"title":"Disease activity and quality of life in patients with systemic lupus erythematosus: a validation study using the SLE-DAS.","authors":"Fung Lam, Kar Li Chan, Chi Hung To, Chi Chiu Mok","doi":"10.55563/clinexprheumatol/1n8j8d","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To study the relationship between disease activity and quality of life (QoL) in patients with systemic lupus erythematosus (SLE) using the SLE disease activity score (SLE-DAS).</p><p><strong>Methods: </strong>Consecutive patients fulfilling the ACR/SLICC criteria for SLE were recruited. Participants were asked to complete the validated Chinese version of the LupusPRO for QoL evaluation before disease activity assessment by SLE-DAS, SLE disease activity index (SLEDAI)-2K and Physician Global Assessment (PGA). Correlation between disease activity and LupusPRO scores, and the effect of SLE-DAS remission on QoL was studied. Patients with active SLE at baseline, defined as a PGA≥0.5, were re-evaluated after 6 months. The change in LupusPRO score was correlated with the change in SLE-DAS.</p><p><strong>Results: </strong>A total of 510 patients were studied (92.9% women; age 48.6 ±13.3 years). At baseline, SLE-DAS remission (score ≤2.08), mild (2.08-7.64) and moderate/high disease activity (>7.64) was present in 364(71.3%), 75(14.7%) and 71(13.9%) patients, respectively. SLE-DAS index-based remission (score ≤2.08 and prednisone ≤5 mg/day) was achieved in 337(66.1%) patients. SLE-DAS correlated significantly with SLEDAI-2K and PGA (rho 0.92 and 0.62, respectively; p<0.01 in both). Patients with SLE-DAS index-based remission reported a significantly higher LupusPRO health-related (HR) QoL score compared to those without (76.8 ±16.2 vs. 69.0 ±16.8; p<0.01). A total of 139 patients with PGA ≥0.5 at baseline were reassessed at month 6: 77(55.4%) patients had improvement in SLE-DAS and 61(43.9%) patients achieved SLE-DAS index-based remission. The change in SLE-DAS was significantly associated with an improvement in LupusPRO HRQoL score (rho -0.30; p<0.01).</p><p><strong>Conclusions: </strong>SLE-DAS remission was associated with better QoL in patients with SLE. Reduction in SLE-DAS over time correlates significantly with improvement in health-related QoL.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":"1227-1234"},"PeriodicalIF":3.4000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and experimental rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.55563/clinexprheumatol/1n8j8d","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/13 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: To study the relationship between disease activity and quality of life (QoL) in patients with systemic lupus erythematosus (SLE) using the SLE disease activity score (SLE-DAS).

Methods: Consecutive patients fulfilling the ACR/SLICC criteria for SLE were recruited. Participants were asked to complete the validated Chinese version of the LupusPRO for QoL evaluation before disease activity assessment by SLE-DAS, SLE disease activity index (SLEDAI)-2K and Physician Global Assessment (PGA). Correlation between disease activity and LupusPRO scores, and the effect of SLE-DAS remission on QoL was studied. Patients with active SLE at baseline, defined as a PGA≥0.5, were re-evaluated after 6 months. The change in LupusPRO score was correlated with the change in SLE-DAS.

Results: A total of 510 patients were studied (92.9% women; age 48.6 ±13.3 years). At baseline, SLE-DAS remission (score ≤2.08), mild (2.08-7.64) and moderate/high disease activity (>7.64) was present in 364(71.3%), 75(14.7%) and 71(13.9%) patients, respectively. SLE-DAS index-based remission (score ≤2.08 and prednisone ≤5 mg/day) was achieved in 337(66.1%) patients. SLE-DAS correlated significantly with SLEDAI-2K and PGA (rho 0.92 and 0.62, respectively; p<0.01 in both). Patients with SLE-DAS index-based remission reported a significantly higher LupusPRO health-related (HR) QoL score compared to those without (76.8 ±16.2 vs. 69.0 ±16.8; p<0.01). A total of 139 patients with PGA ≥0.5 at baseline were reassessed at month 6: 77(55.4%) patients had improvement in SLE-DAS and 61(43.9%) patients achieved SLE-DAS index-based remission. The change in SLE-DAS was significantly associated with an improvement in LupusPRO HRQoL score (rho -0.30; p<0.01).

Conclusions: SLE-DAS remission was associated with better QoL in patients with SLE. Reduction in SLE-DAS over time correlates significantly with improvement in health-related QoL.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
系统性红斑狼疮患者的疾病活动性和生活质量:一项使用SLE-DAS的验证性研究
目的:应用系统性红斑狼疮(SLE)疾病活动性评分(SLE- das)研究SLE患者疾病活动性与生活质量(QoL)的关系。方法:连续招募符合ACR/SLICC SLE标准的患者。参与者在使用SLE- das、SLE疾病活动性指数(SLEDAI)-2K和医师全局评估(PGA)进行疾病活动性评估之前,完成经验证的中文版LupusPRO进行QoL评估。研究疾病活动度与LupusPRO评分的相关性,以及SLE-DAS缓解对生活质量的影响。基线时活动性SLE患者,定义为PGA≥0.5,6个月后重新评估。LupusPRO评分的变化与SLE-DAS的变化相关。结果:共纳入510例患者,其中女性92.9%;年龄(48.6±13.3岁)。基线时,364例(71.3%)、75例(14.7%)和71例(13.9%)患者分别出现SLE-DAS缓解(评分≤2.08)、轻度(2.08-7.64)和中度/高度疾病活动性(>7.64)。337例(66.1%)患者实现了基于SLE-DAS指数的缓解(评分≤2.08,强的松≤5 mg/天)。sledai - das与SLEDAI-2K、PGA显著相关(rho分别为0.92、0.62);结论:SLE- das缓解与SLE患者更好的生活质量相关。随着时间的推移,sled - das的减少与健康相关生活质量的改善显著相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.10
自引率
18.90%
发文量
377
审稿时长
3-6 weeks
期刊介绍: Clinical and Experimental Rheumatology is a bi-monthly international peer-reviewed journal which has been covering all clinical, experimental and translational aspects of musculoskeletal, arthritic and connective tissue diseases since 1983.
期刊最新文献
Assessing the impact of the pandemic on fibromyalgia patients requires methodologically and substantively reliable studies. Two faces of chronic pain: distinct psychosocial profiles in headache and fibromyalgia. Prevention and management of gastrointestinal side effects in patients with systemic sclerosis-interstitial lung disease receiving anti-fibrotic therapy: a modified Delphi consensus study. Validation of the German version of the ANCA-associated vasculitis patient-reported outcome questionnaire. Ocrelizumab in a difficult-to-treat rheumatoid arthritis patient.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1